How BW&CO Helped Olfera Win a NASA STTR Phase I Award for Microgravity Parkinson's Research
Quick Answer
Olfera, a Mountain View biopharmaceutical startup building an olfactory brain-on-chip platform, was selected for a NASA STTR Phase I award under the 2026B-I solicitation, subtopic ORBECON.2.T26B (Biotechnology Applications from Space for Earth). The proposal, ORBECON.2.T26B-0044, will validate Olfera's OChip platform aboard the International Space Station in partnership with BioServe Space Technologies, using microgravity to accelerate the study of Parkinson's disease progression. BW&CO Consulting supported the client end to end, providing proposal strategy, initial drafting, technical and compliance review, editing, and administrative submission support. BW&CO's project consultant Kris Mueller led strategy and Barbara Serafin managed compliance and administrative review.
The Client: Olfera
Olfera is a biopharmaceutical company founded in 2022 and based in Mountain View, California. The company is developing non-invasive therapies for neurological conditions by using the olfactory system as a direct delivery pathway to the brain, an approach that sidesteps some of the limitations the blood-brain barrier creates for conventional drug delivery. Olfera's core platform, called OChip, is an olfactory brain-on-chip that recreates the nose-to-brain neural circuit inside a microfluidic system engineered for directional axonal connectivity.
Olfera has also been selected for the ISS National Lab's Orbital Edge Accelerator program, a cohort focused on incubating space-based research ventures. The NASA STTR Phase I award described in this case study builds directly on that trajectory, giving Olfera a funded path to test its platform in orbit.
The Opportunity: NASA STTR 2026B-I, Subtopic ORBECON.2.T26B
The subtopic, Biotechnology Applications from Space for Earth, calls for space-based biotechnology work with terrestrial health applications. Olfera's proposal, titled "Parkinson's Drug Discovery Accelerated with Olfactory Brain-on-Chip on Earth and in Microgravity," proposed to validate the second-generation OChip platform aboard the ISS in partnership with BioServe Space Technologies.
The scientific premise centers on a well-documented but underused clinical signal. Loss of smell affects the large majority of Parkinson's patients years before motor symptoms appear, making the olfactory pathway one of the earliest sites of disease pathology, yet no existing model had fully recreated that circuit. OChip is built using primary human olfactory neurons collected non-invasively from living donors, including early-stage Parkinson's patients, rather than relying on animal models, induced pluripotent stem cells, or post-mortem tissue. These neurons retain the native epigenetic landscape, pathology, and aging signatures of a living patient, which is difficult to reproduce in other model systems.
The Phase I proposal set out to use microgravity as an accelerant. Spaceflight conditions are known to speed up cellular aging, alpha-synuclein aggregation, and mitochondrial and dopamine pathway dysfunction, compressing a disease process that normally unfolds over decades into a research window that is actually feasible to study. The funded Phase I work will validate OChip aboard the ISS against matched ground controls, quantify Parkinson's-relevant cellular signatures across the nose-to-brain circuit, and test both a disease-relevant environmental toxin and a clinical-stage therapeutic antibody within the same system. The award targets Technology Readiness Levels 3 through 6 and has a duration of 13 months.
Why This Mattered
CNS drug development has one of the worst failure rates in the pharmaceutical industry, and a large share of that failure traces back to preclinical models that do not faithfully represent human disease. A validated, patient-derived model of early Parkinson's pathology, especially one that can be accelerated through microgravity, has real potential to reduce the time and cost of getting new therapies into clinical testing. A non-dilutive federal award let Olfera pursue that validation work without giving up equity or diluting existing investors, while adding a NASA-backed technical milestone to the company's record.
How BW&CO Supported the Proposal
STTR proposals combine a company's commercial narrative with a formal research partnership, in Olfera's case with BioServe Space Technologies, and both halves have to hold together technically, competitively, and administratively. BW&CO worked across the full lifecycle of the proposal:
Strategy. BW&CO helped position Olfera's OChip platform against the specific language of the ORBECON.2.T26B subtopic, sharpening the connection between the company's olfactory drug delivery thesis and NASA's interest in space-based biotechnology with terrestrial health impact.
Initial drafting. BW&CO's project consultant, Kris Mueller, led the initial draft of the technical narrative, translating Olfera's underlying science, the OChip platform, the BioServe ISS partnership, and the Parkinson's disease rationale, into the structure and tone that NASA STTR reviewers expect.
Review and editing. The draft went through iterative technical review and editing passes to tighten the scientific argument, clarify the Phase I objectives, and make sure the proposal read clearly within NASA's character and formatting limits.
Compliance and administrative review. Barbara Serafin managed compliance checks and administrative review, confirming the proposal met STTR program requirements, including the research institution partnership structure required for STTR awards, before submission.
The Outcome
Olfera's proposal was selected for a NASA STTR Phase I award under the 2026B-I solicitation. The award funds a 13-month Phase I effort to validate the OChip platform aboard the International Space Station in partnership with BioServe Space Technologies, positioning Olfera to pursue Phase II funding for continued in-orbit Parkinson's disease research.
Work With BW&CO
BW&CO Consulting helps deep-tech, biotech, MedTech, agtech, and defense-adjacent founders win non-dilutive federal funding through SBIR, STTR, and related mechanisms across NASA, NIH, NSF, DoD, DOE, and ARPA-H. If your company is developing space-relevant biotechnology, dual-use hardware, or early-stage therapeutics and you want a funding strategy built around your actual science, reach out to BW&CO to talk through your fit for an upcoming solicitation.
FAQ
What is Olfera's OChip platform? OChip is an olfactory brain-on-chip developed by Olfera. It recreates the human nose-to-brain neural circuit inside a microfluidic system built for directional axonal connectivity, using primary human olfactory neurons collected non-invasively from living donors, including early-stage Parkinson's disease patients.
What NASA program funded this project? The project was funded through NASA's STTR (Small Business Technology Transfer) program, under the 2026B-I solicitation, subtopic ORBECON.2.T26B, Biotechnology Applications from Space for Earth.
Why study Parkinson's disease in microgravity? Microgravity has been shown to accelerate cellular aging, alpha-synuclein aggregation, and mitochondrial and dopamine pathway dysfunction. Because Parkinson's disease normally progresses over decades, these accelerated conditions compress the disease timeline into a window that is practical to study aboard the ISS.
Who is Olfera's research partner for the ISS validation work? Olfera is partnering with BioServe Space Technologies to validate the OChip platform aboard the International Space Station.
What role did BW&CO play in the proposal? BW&CO supported Olfera across the full proposal lifecycle, including strategy, initial drafting, technical review and editing, and compliance and administrative review ahead of submission. Kris Mueller led strategy and drafting as project consultant, and Barbara Serafin managed compliance and administrative review.
What is an STTR Phase I award? STTR Phase I is the initial, feasibility-stage award under the federal Small Business Technology Transfer program. It requires a formal partnership between a small business and a research institution, and it provides non-dilutive funding to establish technical merit and feasibility before a company can pursue a larger Phase II award.